5-Azacytidine modulates the response of sensitive and multidrug-resistant K562 leukemic cells to cytostatic drugs.

In an endeavor to improve responsiveness of tumor cells to drug combination treatments, we analyzed the effect of 5-azacytidine (5AC) as a model compound for a new class of drugs, DNA-demethylating agents. We used parental K562/WT chronic myelogenous leukemia cells and a multidrug-resistant subline thereof, K562/ADM. Multidrug-resistant cells were more resistant to daunorubicin, but more sensitive to cisplatin than parental K562 cells as measured by growth inhibition and apoptosis assays. Resistance to daunorubicin can be explained by amplification of the MDR1 drug transporter gene. Cisplatin induced more DNA damage in specific genes and in the entire genome of K562/ADM cells compared to K562/WT cells using PCR stop assays and atomic absorption spectroscopy. Pretreatment with 5AC modulated the response of K562/ADM cells toward MDR-type drugs (daunorubicin, vincristine, etoposide) and reduced function and expression of MDR1 as analyzed by flow cytometry and RT-PCR. Analysis of CpG island methylation in the promotor region of the MDR1 gene by bisulfite sequencing and a methylation-sensitive HpaII-digestion/PCR approach revealed that methylation of the MDR1 promotor of K562/ADM cells was greater than in K562/WT cells. 5AC treatment completely abolished MDR1 promotor methylation. The unexpected observation that DNA demethylation by 5AC rather decreases than increases MDR1 expression in K5612/ADM cells points to still unexplored sequences in the MDR1 promotor whose transcriptional activity may be affected by the methylation status. 5AC pretreatment also modulated K562/WT and K562/ADM cells to non-MDR-type drugs such as cisplatin and increased cisplatin-induced DNA damage.

[1]  T. Efferth,et al.  DNA damage and apoptosis in mononuclear cells from glucose‐6‐phosphate dehydrogenase‐deficient patients (G6PD Aachen variant) after UV irradiation , 2001, Journal of leukocyte biology.

[2]  T. Lipp,et al.  Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). , 2000, Hematology/oncology clinics of North America.

[3]  T. Ando,et al.  Decitabine (5-Aza-2′-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells , 2000, Leukemia.

[4]  T. Efferth,et al.  Damage of the kinesin heavy chain gene contributes to the antagonism of cisplatin and paclitaxel. , 2000, Anticancer research.

[5]  J. Rowe.  Treatment of acute myelogenous leukemia in older adults , 2000, Leukemia.

[6]  S. Sacchi,et al.  Chronic myelogenous leukemia in nonlymphoid blastic phase , 1999, Cancer.

[7]  C. Willman,et al.  Methylation analysis of the human multidrug resistance 1 gene in normal and leukemic hematopoietic cells , 1999, Leukemia.

[8]  T. Furukawa,et al.  Resistance to cisplatin. , 1999, Anti-cancer drug design.

[9]  K. Ohshima,et al.  Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. , 1998, Blood.

[10]  J. Rice,et al.  Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells , 1998, Oncogene.

[11]  A. Cann,et al.  The mechanism of trans-activation of the MDR1 gene by human T-cell leukemia virus. , 1998, Biochemical and biophysical research communications.

[12]  M. Davey,et al.  Demethylation of the humanMDR1 5′ region accompanies activation of P-glycoprotein expression in a HL60 multidrug resistant subline , 1997, Somatic cell and molecular genetics.

[13]  J. Zalcberg,et al.  Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  J. Costello,et al.  Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene , 1997, Molecular and cellular biology.

[15]  T. Efferth,et al.  Apoptosis and resistance to daunorubicin in human leukemic cells , 1997, Leukemia.

[16]  E. Estey,et al.  Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia , 1997, Leukemia.

[17]  T. Efferth,et al.  Anti-Fas/Apo-1 monoclonal antibody CH-11 depletes glutathione and kills multidrug-resistant human leukemic cells. , 1996, Blood cells, molecules & diseases.

[18]  A. G. Bosanquet,et al.  Novel ex vivo analysis of nonclassical, pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rationale for treatment strategies in chronic lymphocytic leukemia , 1996 .

[19]  M. Szyf.  The DNA methylation machinery as a target for anticancer therapy. , 1996, Pharmacology & therapeutics.

[20]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[21]  S. Kudo,et al.  Tissue-specific Transcriptional Regulation of Human Leukosialin (CD43) Gene Is Achieved by DNA Methylation (*) , 1995, The Journal of Biological Chemistry.

[22]  R. Weinberg,et al.  Suppression of intestinal neoplasia by DNA hypomethylation , 1995, Cell.

[23]  J. Brooks,et al.  Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Herman,et al.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Miwa,et al.  Molecular study of eight Japanese cases of glucose-6-phosphate dehydrogenase deficiency by nonradioisotopic single-strand conformation polymorphism analysis. , 1994, Blood.

[26]  A. Eastman,et al.  Gene-specific damage produced by cisplatin, ormaplatin and UV light in human cells as assayed by the polymerase chain reaction. , 1993, Oncology research.

[27]  W. Telford,et al.  Comparative evaluation of several DNA binding dyes in the detection of apoptosis-associated chromatin degradation by flow cytometry. , 1992, Cytometry.

[28]  A. Eastman,et al.  A polymerase chain reaction-based method to detect cisplatin adducts in specific genes. , 1991, Nucleic acids research.

[29]  T. Dryja,et al.  Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. , 1991, American journal of human genetics.

[30]  H. Hameister,et al.  Fragile sites induced by 5-azacytidine and 5-azadeoxycytidine in the murine genome. , 2008, Hereditas.

[31]  A. Bird,et al.  High levels of De Novo methylation and altered chromatin structure at CpG islands in cell lines , 1990, Cell.

[32]  J. Nyce.  Drug-induced DNA hypermethylation and drug resistance in human tumors. , 1989, Cancer research.

[33]  I. Roninson,et al.  mRNA phenotyping by enzymatic amplification of randomly primed cDNA. , 1988, Nucleic acids research.

[34]  S. Volinia,et al.  Clustering of undermethylated CCGG and GCGC sequences in the 5' region of the Ha-ras-1 oncogene of human leukemic K562 cells. , 1987, Biochemical and biophysical research communications.

[35]  A. Eastman.  Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. , 1986, Biochemistry.

[36]  A. Look,et al.  Induction failures in childhood acute nonlymphocytic leukemia: etoposide/5-azacytidine for cases refractory to daunorubicin/cytarabine. , 1986, Medical and pediatric oncology.

[37]  L. Norton,et al.  Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. , 1982, Annals of internal medicine.

[38]  J. Christman,et al.  Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. , 1982, The Journal of biological chemistry.

[39]  P. Jones,et al.  Hemimethylated duplex DNAs prepared from 5-azacytidine-treated cells. , 1981, Nucleic acids research.